Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr. Verstovsek on the Role of Ruxolitinib in Myelofibrosis

December 16th 2020

Srdan Verstovsek, MD, PhD, discusses the role of ruxolitinib in myelofibrosis.

Dr. Spivak on Diagnosing Essential Thrombocythemia

December 9th 2020

Jerry L​e Pow Spivak, MD, discusses diagnosing essential thrombocythemia.

Dr. Rampal on the Evolution of Prognostic Models in Essential Thrombocythemia

December 8th 2020

Raajit K. Rampal, MD, PhD, discusses the evolution of prognostic models in essential thrombocythemia.

Driver Mutations Detectable in Utero, Used to Calculate MPN Diagnosis

December 8th 2020

JAK2 and DNMT3A driver mutations can be acquired as early as in utero in patients with myeloproliferative neoplasms, demonstrating variable rates of clonal expansion and growth that influence the time to diagnosis.

Dr. Mesa on the Anticipated Utility of Momelotinib in Myelofibrosis

December 7th 2020

Ruben A. Mesa, MD, discusses the anticipated utility of momelotinib in myelofibrosis.

Dr. Verstovsek on the Results of the PV-AIM trial in Polycythemia Vera

December 5th 2020

Srdan Verstovsek, MD, PhD, discusses findings from the PV-AIM trial in polycythemia vera.

Momelotinib Sustains Long-Term Survival in Patients With Myelofibrosis

December 5th 2020

December 5, 2020 - Momelotinib improved overall survival and sustained efficacy outcomes in patients with intermediate- or high-risk myelofibrosis.

High-Dose Imetelstat Improves Overall Survival and Offers Clinical Benefits in High-Risk Myelofibrosis

December 5th 2020

December 5, 2020 - Patients with myelofibrosis who are relapsed after or refractory to therapy with Janus kinase inhibitors saw better overall survival, spleen response, and symptom response with higher doses of the telomerase inhibitor imetelstat.

Navitoclax/Ruxolitinib Combo Improves Spleen Volume, Symptoms in Relapsed/Refractory Myelofibrosis

December 5th 2020

December 5, 2020 - The addition of navitoclax to ruxolitinib resulted in a clinically meaningful improvement in spleen volume and total symptom score in patients with myelofibrosis who no longer benefited from prior ruxolitinib therapy.

Dr. El Chaer on the Role of Next-Generation Sequencing in MPNs

December 4th 2020

Firas El Chaer, MD, discusses the role of next-generation sequencing (NGS) in myeloproliferative neoplasms.

Dr. Bose on Risk Factors of Essential Thrombocythemia

December 3rd 2020

Prithviraj Bose, MD, discusses risk factors associated with essential thrombocythemia.

Dr. Mascarenhas on the Role of Genetic Testing in MPNs

December 2nd 2020

John O. Mascarenhas, MD, discusses the role of genetic testing in myeloproliferative neoplasms.

Dr. Mesa on the Potential Role of Momelotinib for Myelofibrosis-Associated Anemia

December 1st 2020

Ruben A. Mesa, MD, discusses the potential role of momelotinib in alleviating myelofibrosis-associated anemia.

Dr. El Chaer on the Potential for Combination Strategies With Ruxolitinib in MPNs

November 25th 2020

Firas El Chaer, MD, discusses the potential utility of combination strategies with ruxolitinib in patients with myeloproliferative neoplasms.

Ruxolitinib Is Linked With High Spleen Responses in IPSS Low-Risk Myelofibrosis

November 25th 2020

November 25, 2020 — Ruxolitinib, when administered earlier on in the treatment course, led to high spleen response rates in patients with low-risk International Prognostic Scoring System myelofibrosis.

Idasanutlin Promotes Transient Expansion of TP53-Mutant Subclones in Polycythemia Vera

November 25th 2020

November 25, 2020 - The oral MDM2 antagonist idasanutlin was found to promote expansion of TP53-mutant subclones among patients with polycythemia vera.

Dr. Mascarenhas on the Significance of Pacritinib in Myelofibrosis

November 24th 2020

John O. Mascarenhas, MD, discusses the potential significance of pacritinib in patients with myelofibrosis.

NCCN Grants Category 2A Recommendation to Decitabine/Cedazuridine Combo for MDS

November 23rd 2020

November 23, 2020 - The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes (MDS) to include the combination of decitabine and cedazuridine as a category 2a recommendation for the treatment of adult patients with intermediate- and high-risk MDS.

JAK Inhibitors Continue to Shape Myelofibrosis Paradigm

November 23rd 2020

 John O. Mascarenhas, MD, discusses how the positioning of JAK inhibitors in myelofibrosis has shifted, and also pointed to new agents under investigation.

Dr. Mascarenhas on Emerging Agents in Myelofibrosis

November 23rd 2020

John O. Mascarenhas, MD, discusses emerging agents in myelofibrosis.

x